AC
ACOR

Ascend Capital’s Acorda Therapeutics ACOR Stock Holding History

Ascend Capital’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$3.32M Buy
+1,410
New +$4.36M 0.17% 113
2013
Q4 		– Sell
-1,114
Closed -$4.58M – 239
2013
Q3 		$4.58M Buy
+1,114
New +$4.8M 0.17% 138

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ascend Capital's ACOR Position: Q3 2018 in Review

Ascend Capital opened a new position in Acorda Therapeutics (ACOR) in Q3 2018: 1,410 shares worth $3.32M. The stake represents 0.17% of the portfolio and ranks #113 among its holdings. This is a return to the name: Ascend Capital previously reported a position in ACOR as recently as Q3 2013.

Ascend Capital first reported a position in ACOR in Q3 2013 and has held it in 2 quarters since. The position peaked at $4.58M in Q3 2013. 174 funds tracked by Wall St. Rank hold ACOR as of Q3 2018.

  • Ascend Capital held 1,410 shares of Acorda Therapeutics worth $3.32M as of Q3 2018.
  • Acorda Therapeutics was a new Ascend Capital position in Q3 2018.
  • Acorda Therapeutics made up 0.17% of Ascend Capital's portfolio in Q3 2018, its #113 holding.
  • Ascend Capital first reported a position in Acorda Therapeutics in Q3 2013 and has held it in 2 quarters since.
  • Ascend Capital's Acorda Therapeutics position peaked at $4.58M in Q3 2013.
  • 174 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.